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3About sanu durabilitas 
Sanu durabilitas, the Swiss Foundation for Sustain able 
Development, was established in 2012 by the Swiss 
Training Centre for Nature and Environmental Protec-
tion (sanu), founded in 1989. As a scientific think tank, it 
works together with actors in the field and at educational 
establishments to raise awareness of important issues and 
challenges for the sustainable development of Switzerland 
and to develop and disseminate appropriate solutions. It 
adopts an international perspective, working closely with 
European experts, and sees its work as Switzerland’s con-
tribution to sustainable global development. 
The working groups at sanu durabilitas, which 
comprise members of the Foundation’s board and exter-
nal experts, develop the topics selected. These groups are 
devoted to tackling the increasingly important political 
issue of suitable regulations to safeguard our country’s 
resources of natural, manufactured, human and social 
capital. A convincing solution to this issue is becoming 
increasingly urgent in our quest to ensure the renewa-
bility of our resources and maintain peaceful conflict res-
olution in all groups of society that use these resources. 
The resulting reports and events serve as a source 
of information and guidance for decision-makers in po-
litical, economic, administrative, scientific and civilian 
spheres, and the results are incorporated into research 
projects and training courses. sanu durabilitas works to-
gether with the training and consultancy firm sanu fu-
ture learning ag to ensure that the results are translated 
into practice. 
The next edition of «Durabilitas» will focus on 
the topic of social change and social cohesion and is due 
to be published in 2015. 
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5Introduction
The aim of this report is to examine the development – 
very dynamic, but only partially known by the public – of 
biotechnology. The report investigate the extent to which 
it either poses environmental risks and ethical concerns 
or, conversely, provides an opportunity to increase social 
prosperity by creating a type of economy requiring less 
material and energy consumption and causing less envi-
ronmental pollution. Under the term biotechnology1 we 
combine three uses of genetic resources: targeted breed-
ing, genetic engineering and synthetic biology. The use of 
genetic engineering and gene therapy on humans is not 
dealt with in this report because of the peculiarity of the 
standards applying to it. 
Biotechnology as a technology of the future is 
the subject of much debate in various circles. There are 
therefore discussions about plant and animal breeding 
which are prompted by the concern that a permanent 
yield increase might lead to the loss of native breeds and 
biodiversity. Other disputes revolve around the risks and 
benefits of genetic engineering.2 Another topic area re-
gards the access to genetic resources and the sharing 
of the benefits resulting from their exploitation. Further 
disputes pose the question of patenting living organisms. 
The debate on synthetic biology (for an explanation of 
the term, see page 8) has hardly come to 
the attention of the public so far. Great 
controversy surrounds the debate over 
the limits of the manipulation of hu-
man life. These and other discussion 
fora have hitherto been largely uncon-
nected. They have split into rival camps 
and have been repeating the same positions for years or 
are at risk to fall into such stalemates. 
The purpose of this report is to merge those 
separate debates. We suspect that an overview can be 
achieved by identifying a common point of reference 
for the topics debated. Therefore, al-
though debate has hitherto been spar-
ked on certain phenotypes, like the ap-
pearance of organisms such as “turbo 
pigs”, “killer viruses”, “chimeras”, we 
propose to deal with the genotype. 
This will allow us to recognise that the 
various discussions have something in 
common. They can, hopefully, be made more transpar-
ent by providing a new thematic structure and new ex-
planations, solutions and explanations.
This report first explains its specific approach, de-
termining a resource – genetic programmes – and focus-
ing the debate on it (Chapters 1–5). It discusses the dif-
ferent uses of the resource (Chapter 6) and then turns to 
the question of political and legal measures. They consist 
of sovereign and property rights (Chapter 7), promotion-
al strategies (Chapter 8) and a complex regulation that 
pursues such different objectives as the securing of so-
cial benefits (Chapter 9), the prevention 
of health and environmental hazards 
(Chapter 10), the consideration of ethi-
cally/culturally-defined social attitudes 
(Chapter 11), and finally the fair shar-
ing of the benefits obtained (Chapter 12). 
1) Biotechnology is 
any technological 
application that uses 
biological systems, 
living organisms, or 
products made from 
them to manufac-
ture or modify goods 
or processes for a 
particular use. For 
the purposes of this 
text, we use the 
definition contained 
in Article 2 of the 
Convention on 
Biological Diversity 
(CBD). In this con-
text, whether “prod-
ucts” also include 
biochemical com-
pounds – as the 
Nagoya Protocol to 
the CBD prescribes 
– is irrelevant. 
2) Genetic engineer-
ing is the alteration 
of the genetic ma-
terial of organisms in 
ways that cannot  
be achieved through 
natural crossbreed-
ing or recombina-
tion. We use this 
term in accordance 
with the Gene 
Technology Act (see 
Art. 5 para. 2 Federal 
Act of 21.3.2003 on 
Non-Human Gene 
Technology).
The discussion fora on 
animal and plant 
breeding, the  
risks of genetic engi-
neering, patenting  
living organisms and 
access to genetic  
resources are largely 
unconnected. 
These separate  
discussions can  
be merged, with actors 
focusing on genotype 
as a resource  
in their debates. 
6From the use of phenotypes to the  
use of genetic programmes
Man has always used living natural resources in various 
ways. Microorganisms, plants and animals – man himself 
as an integral part of nature will not be discussed here – 
are bred and propagated for a wide range of purposes: 
for food, cultivation, the manufacture of products, ener-
gy production, convenience (e. g. as pets or landscapes), 
labour, etc. The phenotype-based approach, i. e. based on 
the outward form of living organisms, is typical of this 
exploitation. 
Since the discovery of the chemistry of the ge-
netic makeup of organisms, the direct utilisation of the 
genome3 of organisms has come to the 
fore. The processes of utilisation, as a 
result, no longer intervene merely at 
the level of organisms, populations and 
ecosystems, but also, and increasingly, 
at the more basic level of cells and their 
genomes. Admittedly, genomic altera-
tion has always been the outcome of 
breeding, but it has hitherto availed it-
self of naturally occurring techniques 
such as sexual and asexual reproduc-
tion, mutation, selection, etc. The tech-
nique for effecting immediate, targeted changes to DNA 
and RNA is new. It has enormously expanded the modifi-
cation options and, in particular, it has accelerated them 
because species boundaries that have traditionally been 
decisive for breeding can now be crossed. 
The technique embraces the approximately 
20-year-old genetic engineering of organisms and is 
currently developing into synthetic biology, which not 
only slightly alters existing organisms, but also radically 
changes genomes and merges them into new cells and 
organisms. Its ultimate aim is to be capable of gener-
ating life artificially in the future. In parallel with ge-
netic engineering, breeding methods have also become 
more artificial: for example, the targeted generation of 
mutations. This calls into question the existing system-
atic separation of breeding from genetic engineering/
synthetic biology. But nowadays even traditional, less in-
trusive breeding incorporates the genomic level, since it 
relies on genomic analysis for the selection of individu-
als (e. g. high-yielding cattle). Overall, a very dynamic 
science of biotechnology has emerged, but for the sake of 
this report we mainly focus on the techniques of target-
ed breeding, genetic engineering, and synthetic biology. 
Swiss law follows this shift away from pheno-
types to genomes. To take the example of farming, the 
traditional utilisation of natural resources is regulated by 
agrarian law, spacial planning law, na-
ture conservation law, the law on the 
approval of varieties, the law on the 
protection of varieties, livestock breed-
ing law, etc. The Genetic Engineering 
Act, which concerns the genomic level, 
was added later on. This law is only 
a harbinger of future regulations that 
must take into account the full spec-
trum of genome-based biotechnology. 
In addition to the risk-oriented Genetic 
Engineering Act, another law is being 
developed that concerns the benefits of 
the technique, organising genomic research and deve-
lopment (R&D) processes and providing for the distribu-
tion of their benefits.
In the realms of science, technology and economics and at a legal level, a shift 
away from phenotype to genotype is observed, whose significance has not been 
sufficiently analysed yet. We recommend a more in-depth theoretical analysis, 
societal reflection and political evaluation.
1
3) The entirety of 
the material carriers 
of the hereditary 
information of a cell 
(genotype)
In addition to the 
risk-oriented gene 
technology law, another 
kind of law is being 
developed, which  
organises the genomic 
research and deve-
lopment processes and 
provides for the  
distribution of their 
benefits. 
The current processes 
of utilisation no  
longer interfere merely 
at the level of  
organisms, populations 
and ecosystems, but 
also, increasingly,  
at the more basic level 
of cells and their 
genomes. 
7Fragmentation of the sectors of utilisation 
and their regulation 
As indicated above, the types of utilisation of natural re-
sources are developing and becoming increasingly nu-
merous. In a free society this is welcome and desirable. 
However, as far as the government's measures for regu-
lating and promoting this utilisation are concerned, an 
overall view is required in order to determine which lines 
of development are worth promoting and which need 
to be regulated because of their risks or for distribution 
purposes. Without such an overview, government meas-
ures become fragmented on account of the obstinacy of 
exploiting industries and of short-term political trends. 
The fragmentation is shown by the wide variety of legal 
matters, which are decisive for the utilisation of natu-
ral resources, including their genetic 
makeup. The legal regulations on ag-
riculture have already been addressed 
above. They need to be supplemented 
by norms on forestry and fishing. The 
law on industrial manufacturing pro-
cesses, on marketing hazardous prod-
ucts – e. g. pesticides, fertilisers, chem-
icals – on intellectual property such as patents and trade 
secrets, on research institutions, on tort liability law, on 
waste disposal, etc. should also be discussed. 
Owing to the cross-border development of bio-
technology, an extremely important role is played by in-
ternational trade rules, such as the EU regulations on 
the marketing of food and genetically-modified food and 
feed4, the World Trade Organization's Agreement on 
Sani tary and Phytosanitary Measures, the Cartagena 
Protocol on Biosafety, and the Nagoya Protocol on access 
to genetic resources and benefit-shar-
ing, as well as several agreements on 
the protection of plant varieties and on 
patents, etc. The old and new regula-
tions discussed in this report are based 
on political processes that produce stra-
tegic papers and implementation plans: 
biodiversity strategies, agriculture de-
velopment programmes, biotechnology 
strategies, etc. They are also reflected 
in a variety of ad-hoc authorities, R&D 
institutions, think tanks and NGOs.
The increasing variety of tech-
niques, effects, programmes, organisa-
tions and regulations may easily cause 
disorientation. The sectors tend to 
deal separately with their subject mat-
ters and their points of view. A general 
overview from which an overarching 
strategy could be developed, however, is difficult to ob-
tain. The purpose of the approach suggested here is to 
define the key resource, then to systematically identify 
and assess its utilisation and impact, and – if necessary – 
to establish a set of laws governing it.
2
4) Regulations (EC) 
178/2002 and (EC) 
1829/2003.
Without an overall  
view, government 
measures become  
fragmented because  
of the self-interests  
of resource users.
We propose to start  
by defining the  
key resource, then to 
systematically identify 
and assess its exploi-
tation and impact and 
– if necessary –  
to provide a legal 
framework. This  
approach will make  
it possible to establish 
a common denominator 
for the types of  
utilisation, which are 
usually dealt with  
on a sector-by-sector 
basis.
8The concept of the actor-centred approach 
to resources
The structural starting point for our approach to resourc-
es (Knoepfel 2007) is not biotechnology, but a resource: 
genetic programmes (see Chapter 5). 
This has the advantage of identifying, 
in addition to the opportunities and risks 
of the technology chosen, the utilisation 
potential of the resource, its ownership 
and the holding of the rights of utilisa-
tion on it, as well as the distribution of 
the benefits derived from its utilisation. 
It also alerts to the fact that the utilisation of resources is 
affected by cultural factors. Nevertheless, the techniques 
using genetic programmes are referred to, also from a re-
source-oriented perspective, as biotechnology. 
It is to be noted that, unlike natural resources 
such as water, air, soil, forests, or animals, genetic re-
sources do not become scarce as a result of their di-
rect exploitation. It is true that this involves risks for 
humans and human health, but not through direct ac-
cess (for instance when clearing a forest), because it is 
often enough to pick a few specimens of an organism 
of interest from which a whole R&D line can then be 
worked out. Rather, risks emerge as indirect results of 
R&D processes, for example when a ge-
netically modified plant passes on its 
foreign gene to the environment, caus-
ing system disturbances. 
Our approach centres on actors, 
because not only does it investigate the 
utilisation of resources focusing on its 
impact on certain tangible values (in 
particular benefits, risks, cultural factors, distribution), 
but it also takes into account the actors behind these ef-
fects, since the effects of the utilisation are not only ob-
jective processes, but are also caused, enjoyed, suffered 
and experienced by humans. Only when the public 
voices objections to all this individual-
ly and in the media is there a political 
basis for regulations and the need to 
involve the public in their formulation 
and application in an orderly manner. 
The effects of the  
resource utilisation are 
caused, enjoyed,  
suffered and experi-
enced by humans.  
Only when the public 
voices objections  
to all this, is there  
a political basis for 
regulations. 
Our approach to  
resources does  
not take biotechnology  
but a resource  
– genetic programmes – 
as its starting point.
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9The actors and their rivalries
For an analysis of the current and future debates it is nec-
essary to identify the main actors who make direct use of 
genetic programmes or are indirectly involved with them. 
Mention should be made of:
• Public and non-profit institutions that conduct research 
in the fields of green biotechnology (agriculture), red 
biotechnology (pharmaceuticals and cosmetics) and/
or industrial biotechnology (energy generation, data 
processing, etc.)
• For-profit companies that conduct research and devel-
opment in the above fields 
• Interest groups in the fields of agriculture, pharmaceu-
ticals, cosmetics and industry 
• Non-governmental organisations in the fields of con-
sumer protection, environmental protection and 
ethics
• Authorities responsible for agriculture, economy and 
trade, health, environment, ethics, research and 
innovation
• Media
• Politics
• Churches and religious communities.
Various rivalries emerge among actors, around, for exam-
ple, research funds, scientific prestige, profit opportuni-
ties, cultural assessments, management 
potential, health and environmental ef-
fects and much more. Underlying these 
rivalries is a conflict of a more funda-
mental nature, one concerning the 
limits of man's alteration of nature, in 
other words the dilemma between pre-
serving genetic resources and creating 
new ones. While supporters of preservation insist that 
the genetic makeup resulting from evolution has enough 
potential to be raised and carefully im-
proved by working on phenotypes (in 
particular, by breeding), proponents 
of creation maintain that it opens up a 
new world of artificial organisms which may ensure in-
creasing levels of well-being and prosperity.
In this report we try to find a solution to the conflicts 
among actors involved in the utilisation of genetic re-
sources as well as to the fundamental conflict over the 
limits of man's alteration of nature, through five key ques-
tions. These are:
• Who should own genetic programmes and the results 
of the research and development conducted based on 
them?
• What social benefits do the use and modification of ge-
netic programmes provide? What economic profit op-
portunities and inherent utility arise?
• What risks to society and the environment are posed 
by the use of genetic programmes, how can those risks 
be minimised and what risks may be taken consider-
ing possible benefits?
• Who should benefit from the use of genetic pro gram- 
mes?
• What limits do cultural and ethical factors impose on 
the modification and use of genetic programmes?
The conflicts over utilisation have given rise to regula-
tions, which have to be analysed individually. Our top pri-
ority in a rational management of resources is, in princi-
ple, their sustainable exploitation. We advocate a “strong” 
version of sustainability, which gives 
priority to the preservation of the 
natural basis of life over short-term 
social and economic benefit. 
Various rivalries 
emerge among actors, 
around research  
funds, health and envi-
ronmental effects, 
profit opportunities etc.
The conflicts over  
utilisation give rise to 
regulations. 
Our focus in the  
following analysis is 
the sustainable  
use of the resource  
in question.
4
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Characterization of the  
“genetic programmes” resource
5.1 Conceptual scope
Since, as previously mentioned, the genetic makeup of 
organisms is becoming increasingly important for recent 
scientific and economic developments, it is recommended 
that it be understood and described in detail as a sepa-
rate resource. It should be considered whether the term 
“genetic resources”, which was introduced by the Con-
vention on Biological Diversity of 1992 (CBD), can be used 
in this broader context. The CBD defines “genetic resour-
ces” as any material of plant, animal, microbial or other 
origin containing functional units of heredity of actual 
or potential value.5
The “value” component referred to in the above 
definition has no particular distinguishing content be-
cause almost everything in this world has at least a poten-
tial value, even if only the value of the 
mere preservation of the resource it-
self. The “material”, “origin” and “units 
of heredity” components of the defini-
tion are more important. The “mate-
rial” nature of the resource differen-
tiates it from the knowledge about it. 
Of course, possessing that knowledge 
is not negligible, but knowledge is rele-
gated to the category of utilisation pro-
cesses, as the object and product of tra-
dition – the CBD bases the protection 
of traditional knowledge of genetic resources on this – 
and of modern R&D.
The “origin” component of the definition refers 
both to nature as a source and to genetic engineering, 
which is also included because it is based on the altera-
tion of natural organisms, while a large area of synthetic 
biology is not and is therefore not in-
cluded. This is a new technology that 
radicalises genetic engineering by 
synthetically manufacturing cell con-
tents (DNA, proteins) on an increasing-
ly large scale, giving them new forms 
that do not occur in nature (Baldwin 
et al. 2012). The further this process of artificialization 
progresses, the further synthetic biology moves from its 
natural origins. Since, however, synthetic biology should 
be included in this analysis to a quite large extent, it is 
advisable to define the underlying resource regardless of 
the CBD terminology.6
This also proves reasonable as regards the “units 
of heredity” component in the concept of genetic re-
sources, because synthetic biology manufactures not 
only cells capable of hereditary transmission, but also 
cells that cannot reproduce themselves, as well as sub-
cellular material, i. e. material found at an infra-cellular 
level, the so-called bio parts, which are not viable alone 
but are able to survive within host organisms. Since they 
are intended to be included in the spectrum of this ap-
proach, the definition of the resource should not be lim-
ited to units of heredity capable of reproduction. 
We therefore propose to define DNA and RNA 
sequen ces as the sources of the socio-economic develop-
ment to be analysed and to describe it as a genetic pro-
gramme. It can be of either natural or artificial origin. It 
is normally found in cells or incorporated into them, but 
can also be produced and used separately at a subcellu-
lar level.
5) Combination of 
items 6 and 8 of 
Article 2 of the CBD. 
6) It should be re-
membered that the 
definition of “genetic 
resources” according 
to CBD also com-
prises “other origin”. 
This may mean 
synthesis and artifi-
cial design. Since 
Article 15 (1) of the 
CBD recognises  
the “sovereign rights 
of States over their 
natural resources”, it 
can be concluded 
that term “sovereign 
rights” also refers to 
the genetic resourc-
es artificially created 
in a State. Thus, they 
could even be de-
rived from the CBD.
The term “genetic  
resources”, introduced 
by the Convention  
on Biological Diversity 
of 1992 (CBD), is  
not sufficient in this  
broader context  
because it does not 
include artificial 
sequences. 
We use the broader 
term “genetic  
programmes”, which 
also includes the  
products of synthetic 
biology. 
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5.2 Materiality and originality of genetic programmes
Genetic programmes are to be understood as real, exist-
ing matter and as their potential effect, as nature's ob-
jective, effective “information” and not 
merely as man's subjective intellectual 
knowledge about that information.7 Of 
course, this knowledge is essential for 
understanding and using genetic pro-
grammes. The objective programme is 
visualised on a computer. If the genetic 
programme needs to be changed, first 
it is modelled on the computer. Some 
refined in silico programming makes 
many experimental steps of in vitro programming – i. e. 
programming in the lab – superfluous. Nevertheless, it 
should be noted that the resource at issue is an objec-
tive fact. 
The greater the proportion of synthetic and arti-
ficial design, the more chemistry-based the nature of the 
resource becomes. Life, however defined, whether as the 
ability to metabolise, the ability to grow, or the ability to 
reproduce, then appears only to be a property of certain 
combinations of chemical molecules (Church 2012). This 
contrasts with the “vitalist” idea that life is a prima-
ry force that has unfolded enormously 
during evolution (Schelling 1799, 80; 
Bergson 1941, 85, 103, 232). Although 
the mechanistic view of natural scienc-
es prevails, there are questions to which 
it still can provide no convincing an-
swer: Where does the life that chemical 
molecules are believed to contain come 
from? Can life be created chemically or 
mechanically? Even if this were possi-
ble, could the faint flicker of partial life-like functions 
– which can be obtained if need be – come close to the 
well-ordered diversity of “life's grandeur” (Gould 1997) 
created by evolution?
For these reasons we understand genetic pro-
grammes to be such that even if produced artificially, 
in origin they contain natural life that they cannot cre-
ate alone. 
7) Of course, the 
objective existence 
can also simply  
be thought of, but 
the content of that 
thought is different 
depending on  
whe ther a physical 
material or a mental 
construct is ima-
gined. Spotting this 
difference has pro-
ved pragmatically 
useful. See the con - 
cept of “objectivity 
in parenthesis”  
of the constructivist 
Maturana (2000: 
226 et seqq.)
Genetic programmes 
are to be understood  
as real, existing  
matter and as their 
potential effect, not 
merely as man's  
intellectual knowledge 
about that potential.
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5.3 Location of genetic programmes
Genetic programmes are contained in organisms, i. e. 
microorganisms, plants and animals, whether occur-
ring in nature or artificially altered. In addition they are 
found in cell cultures or exist as independent subcellular 
units. Being a component of organisms, they are kept in 
the environment (in situ) or in an artificial environment 
(ex situ), such as botanical gardens or laboratories. Cell 
cultures, conversely, are entirely dependent on the labo-
ratory environment (in vitro). 
The place in which a genetic programme is found 
can be determined geographically and by state borders. 
Genetic programmes can also be exported and impor-
ted. This raises the question of to what 
extent genetic programmes from inter-
nal sources can be used, imported and 
exported in a given State, and to what 
extent they can be produced and mar-
keted abroad under the control of that 
State, in natural or modified forms, as 
the case may be.
Switzerland, for example, uses 
genetic programmes available locally 
in the fields of breeding and of the ge-
netic modification of seeds, livestock and microorgan-
isms. Its R&D facilities maintain close contacts with for-
eign institutions. For a limited number of crop species, 
plant material is exchanged within the framework of the 
so-called Multilateral System of the International Trea-
ty of Plant Genetic Resources for Food and Agriculture 
(ITGRFA) (Kamau 2013). For further plant species, for 
animal species and for microorganisms, exchange 
practices are included in a variety of rather informal 
transnational networks (Chiarolla/Louafi/Schloen 2013; 
Biber-Klemm/Temmermann 2011). Switzerland also 
possesses its own ex situ collections of plants, animals 
and microorganisms. In the future, collections of bio 
parts and recombined, i. e. new genetically composite, 
cells and organisms are likely to be added. Those collec-
tions provide an infrastructure and a “bank” to serve a 
variety of uses. But they are also costly to run, and their 
purposes must therefore be justifiable.
As far as genetic engineering is concerned, inter-
nal release experiments with genetically modified seeds 
are allowed very hesitantly because of 
public protests.8 Commercial cultiva-
tion at this time cannot be authorised at 
all owing to the moratorium adopted by 
the Swiss Federal Assembly and extend-
ed to 2017. However, the Swiss R&D in-
stitutions, which are active in this field, 
perform release tests abroad. There they 
have also obtained authorizations for 
marketing genetically modified seeds, 
food and feed. For instance, Syngen-
ta owns EU approvals for eight vari-
eties of genetically modified maize.9 
The marketing of genetically modified 
products abroad is thus arranged and 
managed from Switzerland; however, 
those products are not necessarily in 
their home market. 
We suggest that national and cross-border collections, exchange networks, and 
research and development activities related to genetic programmes in Switzer-
land be surveyed in a separate study and evaluated as to their performance and 
cost.
8) So far four release 
tests have been 
approved, namely 
those conducted  
in 1991 and 1992  
by the research 
institute Changins  
(now Agroscope 
Changins-Wäden-
swil, ACW) with 
virus-resistant  
potatoes, those of 
2004 performed  
by ETH Zurich  
with bad-smelling 
smut-resistant  
wheat and those of 
2013, conducted  
at the University  
of Zurich with  
mildew-resistant 
wheat.
9) EU Register of 
Authorised GMOs, 
available at http://
ec.europa.eu/food/
dyna/gm_register/
index_en.cfm
The place in which  
a genetic programme  
is found can be  
determined geographi-
cally and by state  
boundaries. Genetic 
programmes can  
also be exported and 
imported.
Collections of  
organisms provide an 
infrastructure  
and a “bank” to serve  
a variety of uses.
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Utilisation processes 
6.1 Techniques
Utere, fruere, fungere – the use of a thing, the taking of 
fruits and the transfer of the thing – are the typical uses of 
dead and living resources owned by a person, as defined 
in civil law since Roman times: a cow is used as a draught 
animal or for its meat, as a milk-producing animal it bears 
fruit, and it can be bought and sold. The “use” aspect has 
long included the modification of an object as well, to 
enable it to provide a greater yield. This modification has 
been radicalised by three new techniques, namely target-
ed breeding, genetic engineering and synthetic biology. 
They are summarised here under the term biotechnology. 
Animal and plant breeding traditionally consists in select-
ing the best from among different offspring and letting 
them reproduce, thus exploiting naturally occurring mu-
tations. However, more artificial and targeted methods 
have been developed that, without being genetic engi-
neering as defined by law, achieve a depth of interven-
tion similar to that of genetic engineering.10 This leads to 
faster, safer performance, but it also increases the risks 
of adverse effects on animal welfare, consumers' health, 
the environment, etc.
The depth of intervention of modern breeding techniques questions the bound-
aries between breeding and genetic engineering. We therefore recommend the 
reconsidering of these boundaries between by law defined genetic engineering 
and modern breeding techniques.
Classic genetic engineering is defined by law as the mod-
ification of the genetic material of organisms in ways that 
cannot be achieved through crossbreeding or natural re-
combination alone.11 This is usually done by isolating 
certain genes that contain a programme for a desired 
characteristic (in other words, that “code” for it) from a 
parent organism and inserting them into a host organ-
ism. Take for example the gene coding for insulin, which 
is introduced into a bacterium from a pig and then pro-
duces insulin.
Synthetic biology radicalises this technique by 
fully removing a cell and replacing its content through 
genes from other organisms or with a new design. 
Xenobiology goes even further, replacing the four nucle-
otides (i. e. the bases adenine, thymine, guanine and cy-
tosine), which are the only building blocks of all known 
genomes, with other bases. Modularization and mech-
anistic thinking are typical of synthetic biology: the 
highly complex genetic programmes are divided into 
modules, which code for certain properties. The cell is 
reduced to a minimum viable unit or synthesised as such 
(as a so-called protocell). The modules are then incorpo-
rated into this minimal cell that acts as a “chassis”. This 
creates a new organism with – in theory – precisely de-
fined functions and living conditions, which can be use-
ful but also risky for the environment.
Synthetic biology radicalises the redesign of existing organisms and questions 
therefore its boundary versus genetic engineering. We recommend the reconsid-
ering of this boundary as well. 
10) Without explain-
ing them in detail, 
we give only their 
names here:  
agroinfiltration, 
cisgenesis, intra-
genesis, oligonucleo-
tide-directed  
mutagenesis, graft-
ing, RNA-directed 
DNA methylation, 
reverse breeding and 
zinc finger nuclease. 
See Vogel (2012), 
p. 98. 
11) Art. 5 para. 2 
Gene Technology 
Act.
6
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6.2 Research and development processes
The process of valorisation of genetic programmes using 
biotechnical methods presupposes some knowledge (tax-
onomy) about the host of a genetic programme and about 
its living conditions. It continues by breaking down the 
genome into its single genetic programmes (sequencing), 
goes on to manipulate the programme and obtains mod-
ified organisms that generate certain desired products or 
processes (known as derivatives).
6.3 Types of utilisation
The directions in which the valorisation of genetic pro-
grammes evolves can best be structured by dividing bio-
technology into different types. Four areas are usually 
distinguished: green biotechnology is engaged in agri-
culture (e. g. seeds, animal breeding), red biotechnology 
deals with medicine and pharmaceuticals, white biotech-
nology with the industrial production of various products 
such as food, chemicals (e. g. acetone, butanol), drugs (e. g. 
aspirin), fuels (e. g. bioethanol), vitamins, amino acids 
and many more, and blue biotechnology with marine 
organisms (e. g. transgenic fish, heat-stable enzymes for 
detergents). 
The following areas, which are structured based 
on the product generated, are of interest to Switzerland: 
agricultural products (including forest products and fish), 
energy, environmental management (e. g. plant protec-
tion by microorganisms), waste treatment (e. g. treat-
ment of contaminated soils), medical and pharmaceuti-
cal applications (e. g. diagnostics, drugs), and cosmetics. 
In synthetic biology, the areas of interest are computing 
applications (biochips), applications for 
artistic purposes (self-organising and 
growing paintings and sculptures) and 
applications for creative experimenta-
tion and leisure.12 The fact that the in-
creasing standardisation of synthetic 
biology is creating a new industry that contributes to the 
R&D process through genome sequencing and DNA-syn-
thesising should not be neglected. 
We recommend investigating further whether the lines of development of bio-
technology in Switzerland offer the best opportunities for insights and utilisa-
tion, or whether other lines should be developed.
12) See Church/
Regis 2012, p. 189 et 
seqq., for the devel-
opments of synthetic 
biology in the US 
garage culture.
In synthetic biology 
computing applications 
(biochips) are to be 
expected, in particular.
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6.4 Public and private spheres of use
The concept of spheres of use should help determine 
whether the use of genetic programmes occur more often 
in the private than in the public sector. In Switzerland, 
as in most other countries, mainly public 
institutions conduct research. They con-
duct basic research to understand living 
organisms and life. Public institutions, 
however, are increasingly involved in 
the field of genetic manipulations and in 
the development of products. Converse-
ly, commercial private institutions tra-
ditionally focus on application-oriented 
development activities. However, they 
also conduct basic research, in particular 
where it regards commercially exploita-
ble genetic programmes. 
In addition to the institutional 
dimension (private/public) and the di-
mension of contents (basics/application) 
of R&D, it is significant whether R&D re-
sults are privatised based on intellec-
tual and factual property or are made available within 
the public domain.13 Public institutions – such as uni-
versities – that traditionally work for the public domain 
are increasingly looking for the protection of intellectual 
property rights in order to generate profits from their 
R&D results. Those types of privatization counteract a 
trend towards strengthening the public domain, which 
makes research results available to the 
general public at low cost. This occurs 
increasingly through electronic tools, 
particularly databases. Research re-
sults can be structured into databases 
concerning the genetic level (such as 
GenBank for genes and UniProtKB and 
SwissProt for proteins) and into databas-
es covering the organismic and ecosys-
tem levels (such as the Global Biodiver-
sity Information Facility GBIF) (Fedder 
2013; Winter 2013). For synthetic biol-
ogy, materials and bio parts databas-
es are also available (Baldwin 2012). 
Private institutions are also largely in-
volved in the maintenance of the pub-
lic domain, as far as basic knowledge, 
which is not directly exploitable, is con-
cerned. Because of this mix of functions, a clear differ-
ence between publicly and privately funded R&D is bare-
ly recognizable. This needs to be reconsidered and must 
bear consequences on public funding programmes. 
As a basis for political discussions and decisions, we recommend further investi-
gation of the extent to which the R&D process aims at privatization or at bringing 
its findings to the public domain, as far as genetic programmes are concerned.
 
13) Public domain is 
defined as a body  
of knowledge, which 
is freely accessible  
to everybody and 
may be further deve - 
lop ed. The public 
domain can also 
refer to material or 
products, which  
may then be used by 
anybody free of 
charge or for admin-
istrative fees only. 
Public institutions  
– such as universities – 
that traditionally  
work for the public  
domain are increasingly 
looking for the  
protection of their  
intellectual property 
rights in order to  
generate profits from 
their R&D results.  
Such types of privatiza-
tion counteract the 
trend towards a 
strengthening of the 
public domain.
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Sovereign and property rights
7.1 General aspects
Property rights are to be distinguished 
from regulations on the use of property. 
Property in principle assigns a resource 
to an owner, who may bar others from 
using it and may resist government in-
tervention in the use of the resource. Al-
though the use may be limited by regu-
lation, this is subject to proportionality 
and – if the property is seized – to compensation. Because 
of the importance of this basic assignment, the question 
of ownership must also be raised for genetic programmes. 
The question of ownership is relevant at an inter-
national level as the question of the sovereign rights of 
a State. They represent the fundamental attitude of one 
State towards other States, in that it may bar other States 
from the utilisation of its resources. 
Sovereign and property rights are part of the 
fundamental conflict between the private and the col-
lective spheres. This conflict over genetic programmes 
regards all forms in which the pro-
grammes appear in the process of val-
orisation, namely as a component of a 
host organism, as information resulting 
from R&D conducted on them, and as 
a modified programme in an organism 
which is marketed under certain cir-
cumstances. Appropriation or commu-
nality appear at an international level 
as trends towards sovereignty and/or 
the common good and at a national 
level as trends toward either private or 
common property. States are divided 
on the question of whether they prac-
tice appropriation or communality ex-
ternally and/or internally (Chart 1). 
The design alternatives will be examined in even 
greater detail with reference to the three stages of valori-
sation in the following chapters.
International level
Sovereignity of the state or 
common good of Mankind?
Process of 
valorisation
Stage 1:
Organism with 
original genetic 
programme
Stage 2:
Information from 
research and 
development
Stage 3:
Organism with 
modified genetic 
programme
Domestic level Private property or  
common property?
Chart 1: Sovereign and property rights in the process of the valorisation of genetic programmes. The stages 1 to 3 will be 
described in even greater detail in the following chapters.
States are divided  
over the question  
of whether they prac-
tice appropriation or 
communality externally 
and/or internally. 
An owner may  
bar others from utilisa-
tion. A State too  
has ownership of a  
resource if it may  
bar other States from 
its utilisation.
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7.2 Property rights on the original genetic programme 
In compliance with the internationally acknowledged 
principle of the territorial sovereignty of States, the ju-
risdiction of each State also extends to the plants, ani-
mals and microorganisms living in its territory or coastal 
waters, as well as in its exclusive economic zone and 
continental shelf (Chart 1, Stage 1). With this principle 
traditionally applying to phenotypes, the decision as to 
whether the genetic makeup of organisms should be con-
sidered State property or public domain of Mankind re-
mained a controversial issue for a long 
time. A valid argument in favour of the 
latter is that the genetic makeup of spe-
cies is identical across borders and sub-
ject to only marginal local and individu-
al variations, which, in any case, do not 
follow political borders. However, de-
veloping countries struggled to impose 
the predominance of State ownership 
and the CBD of 1992 recognised the 
sovereign rights of States over “their” 
genetic resources.14
No final decision has been 
made in Switzerland about the rights 
to ownership of genetic resources. The ownership of the 
plant rests irrefutably with the farmer cultivating it, who 
also materially owns the plant's genetic material. How-
ever, the genetic potential that is present in the plant is 
not a property and remains “unowned”.
Access to genetic resources in Switzerland is per-
mitted to non-proprietors, including foreign users, who 
can freely access, research and further develop the genetic 
resources present in the country. Nonetheless, the own-
ership of the plant or animal in which 
the genome is located must be respect-
ed, i. e. the genome may be extracted 
only with the owner's consent, unless 
such extraction is considered common 
practice. Obviously, users must also 
comply with environmental laws, in-
cluding laws on the protection of rare 
plant and animal species and hunting 
regulations. In its capacity as a State that can grant ac-
cess to its genetic resources (so-called “Provider State” 
according to the definitions of the Nagoya Protocol), 
Switzerland has exercised its sovereign rights so far by 
granting free access to these resources. 
14) Art. 15 (1) CBD.
The decision as  
to whether the genetic 
makeup of organisms 
should be considered 
State property or  
the public domain  
of Mankind remained a 
controversial issue  
for a long time.  
Nowadays, States are 
attributed sovereign 
rights on their genetic 
resources.
Up until now,  
non-proprietors and 
foreign users could 
freely access, research 
and further develop  
any genetic resources 
located in Switzerland.
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7.3 Property rights on research and development based information 
about genetic programmes
The question of private or collective 
ownership arises also in connection 
with information obtained through R&D 
activities (Chart 1, Stage 2). A distinction 
should be drawn here between patent 
law and copyright. 
a) Patent law: Information on gene se-
quences, that is DNA chains forming 
the genetic program, is patentable. In 
the past, this approach was advocated and also partially 
implemented for sequences, while today it is generally re-
quested that the function for which the sequence codes 
be described.15 Likewise, microorganisms that are iden-
tified taxonomically can be patented.16
A problem is posed by the fact 
that these are not inventions, but rath-
er discoveries of natural phenomena.17 
As a rule, no absolute rights are grant-
ed for certain types of discoveries, as 
in the case of a chemical compound, 
a star, a mathematical formula and so 
on. This privilege could almost be seen 
as a violation of the equality principle. 
Furthermore, patent rights on discover-
ies are widely believed to hamper R&D 
activities in general (Rimmer 2008). On 
the other hand, one could hardly argue 
that no investments would be made in 
research if the findings could not be pat-
ented. For the basic research under discussion here is 
conducted to a large extent by publicly funded research 
centres, or at least this would be the case if private re-
search were abandoned because of the impossibility of 
obtaining patents. 
The unrestricted patenting of discovered gene 
functions actually reinforces the trend towards the mod-
ification of genetic programmes. At the root of these 
developments lies a lack of awareness of the nature of 
organisms and their environments that can only be un-
derstood and developed through a holistic approach. 
Our general opinion is that discoveries regarding genetic programmes should be 
understood as improvements to the shared knowledge of society. We therefore 
recommend that Switzerland vote against the patentability of discoveries in 
international negotiations. Patents should be admissible only in the later stages 
of the process of valorisation of genetic programmes.
15) Art. 1 b para. 2 
and Art. 8 c Patents 
Act (Federal Act of 
25.6.1954 on Patents 
for Inventions)
16) Art. 2 para. 2 lit. 
b Patents Act
17) Patent laws in 
the USA exclude 
natural phenomena 
from patenting; see 
35 U.S.C. § 101 in 
the Interpretation of 
the Supreme Court. 
Cf. the very clear 
distinction drawn in 
the case Association 
for Molecular Pathol-
ogy, et al. v. Myriad 
Genetics, Inc. 569 
U.S. (2013) and US 
Patent and Trade 
Mark Office (2014).
Information on gene 
sequences, so  
DNA chains forming the  
genetic program, are 
patentable, on condition 
that a description of  
the sequence's function 
is provided.
Patent rights on  
discoveries are  
widely believed to  
hamper R&D activities 
in general.
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b) Copyright: Information on genet-
ic programmes concerns not only pat-
ent rights, but also copyrights. Broadly 
speaking, patent law can be said to fo-
cus on the content of information and 
especially on its commercial applica-
bility, while copyrights focus on the 
form of information and especially on 
its utilisation for publication. Also the 
private property right based on the cop-
yright is seen in antithesis to collectiv-
ity or public domain. The opportunity exists for authors 
to surrender their intellectual property and make their 
information freely available to the gener-
al public, as for example in open access 
databases. Several templates are avail-
able for this purpose, e. g. the “Creative 
Commons Licence”.18 At first glance, this 
liberalisation may appear to be in favour 
of R&D processes. However, it should be 
considered that publishing media deserve 
some revenue to survive, insofar as they 
ensure the quality of information, provide 
archiving capacity, systematise informa-
tion, make it more easily accessible etc., and need to be 
financed somehow.
We recommend that the findings from basic research on genetic programmes 
should become part of the public domain as much as possible. However, pro-
visions should also be taken to make sure that the costs for the unbiased and 
lasting storage and availability of the relevant data are covered.
18) http://creative 
commons.org/
licenses/by/2.5/au/
legalcode
Patent law focuses  
on the content  
of information and  
especially on its  
commercial applica-
bility, while copyrights  
focus on the form  
of information and on  
its utilisation for pub- 
lication.
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7.4 Ownership of genetically modified organisms
Intellectual property rights can be claimed for organisms 
modified through either breeding or genetic engineering 
(Chart 1, Stage 3). Seeds are regulated by plant variety 
rights based on the law for the protection of new plant 
varieties, while patent rights apply to modified micro-
organisms. Animal species and plant varieties are not 
covered by patents.19 Units at sub-organism level such as 
modified cells and modified gene sequences continue to 
be patentable. 
Plant variety rights grant more limited absolute 
rights than do patent rights. Plant variety rights permit 
continuation of breeding (derogation 
for breeders) and growing of propagat-
ing material for own use (derogation 
for farmers).20 Switzerland did not im-
plement the clause of the Convention 
for the Protection of New Varieties 
of Plants of the International Union 
for the Protection of New Varieties of 
Plants (UPOV Convention) setting out 
that propagation for own use may be 
subject to a plant variety right-holder's fee.21 The exemp-
tion of farmers from the payment of a propagation fee is 
appreciated because it supports the promotion of small-
scale farming. We suggest examining the effects of this 
regulation in practice.
Patent law tends to overlap with 
plant variety protection rights. This hap-
pens mostly in four ways:
1. More and more often, gene sequen-
ces with specific traits are intro-
duced in plants. If they are covered 
by patent, the patent extends also to the utilisation 
of the plant.22 
2. When the introduced gene modifies the plant signi-
ficantly, the latter becomes a product obtained with 
the help of microbiological processes. As such, the 
plant becomes patentable.23
3. Inventions that concern several plant varieties can 
be patented.24
4. The exclusion from patenting of “essentially biologi-
cal procedures for plant production” and their pro-
ducts is increasingly being questioned. It is argued 
that traditional breeding methods – which are the 
reason for the mentioned exclusion 25 – have been 
replaced by modern and more accurate methods 
with a technical quality level that now equals that of 
microbiological methods. 
A similar trend can be observed in animal breeding. Un-
like plant varieties, animal breeds do not enjoy sui generis 
protection rights, and this has given rise to complaints 
by some breeding companies. However, there have been 
several developments that have actually expanded patent-
ing possibilities: first, patentability of individual animals 
that do not constitute an animal breed, as for example the 
onco mouse developed for carcinogenicity testing. Second, 
patentability of extraneous gene sequences which are 
transferred to an animal by means of mi-
crobiological procedures. Third, patenta-
bility of modified or discovered gene se-
quences that several animal breeds have 
in common and fourth, of the more ad-
vanced high technology breeding meth-
ods (Biber-Klemm/Temmermann 2011).
19) Art. 5 Federal 
Act for the  
protection of new 
plant varieties  
(Bundesgesetz vom 
20.3.1975 über den 
Schutz von Pflanzen-
züchtungen);  
Art. 2 para. 2 lit. b 
Patents Act.
20) Art. 6 lit. c and 
art. 7 Federal Act for 
the protection of 
new plant varieties.
21) Art. 14 para 2 
UPOV Convention. 
Cf. Lochen (2007) 
p. 77.
22) Art. 8 b Patents 
Act
23) Art. 2 para. 2 
lit. b Patents Act.
24) Art. 2 para. 2 
lit. b Patents Act.
25) Art. 2 para. 2 lit. 
b Patents Act.
Plant variety rights 
apply to seeds, patent 
rights apply to modi-
fied microorganisms. 
Animal species and 
plant varieties are  
not covered by patents 
in Switzerland.
When the introduced 
gene modifies the  
plant significantly, the  
latter becomes a  
product obtained with  
the help of micro-
biological processes.  
As such, the plant  
becomes patentable.
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These developments have increasingly 
submitted the plant and animal realm 
to patent law with adverse consequen ces 
for small-scale farming, as the opportu-
nities for own breeding have been re-
duced and the costs for seeds and breed-
er animals have risen. Besides shifting 
income opportunities, this trend jeop-
ardises the very survival and breeding 
of traditional and diverse native breeds. 
Farmers wishing to propagate protected 
plant varieties can still do so. However, 
they need the authorisation of the patent-holder for a spe-
cific plant trait before they can sell the plants. Alterna-
tively, they have to breed out the trait. If a farmer owns 
a patent for the plant variety, he can continue breeding in 
Switzerland;26 however, authorisation before distribution 
is needed also in this case, unless all com-
ponents covered by patent are bred out. 
Moreover, the modularity of traits and 
the presence of several patent-holders 
pose a problem for industrial breeding 
too, because of the need to obtain an in-
creasing number of approvals from other 
subjects. Patent pools provide a way out 
of this problem. However, patent pools 
lead to closed shops that are shielded 
against competition and resemble an oli-
gopoly. As a result, small farmers remain 
largely excluded from such patent pools (Gelinsky 2013). 
Intellectual property rights owners are progressively tak-
ing possession of living things, thereby accelerating the 
ongoing industrialisation of farming with all its critical 
social and environmental consequences.
We therefore recommend exploring ways of limiting patentability in the plant 
and animal domains. 
Intellectual property 
rights owners  
are progressively taking 
possession of living 
nature, thereby  
accelerating the on-
going industrialisation 
of farming with  
all its critical social 
and environmental 
con se quences.
26) Art. 9 para. 1 
lit. e Patents Act.
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Strategies for the promotion of research and 
development activities
Switzerland promotes R&D activities on genetic pro-
grammes by providing project-based financing and a 
research infrastructure. Other forms of funding are 
provided in parallel by the private sector. All types of 
applications are supported by either private or public 
funding. It is difficult to have a complete overview of 
these activities. Due to the very dynamic development 
of biotechnology, there is a risk that research funding 
and researchers are lured into following fashion hypes. 
Especially the synthetic biology is often proposed as the 
solution – in theory – to many problems 
(Schummer 2011). Importantly, the pro-
motion of research on novel biotechno-
logies should be linked to research on 
their effects on health and the envi-
ronment, as well as to studies on the 
social and cultural perception of these 
innovations. The National Research Programme 59 on the 
benefits and risks of the release of genetically modified 
plants is a favourable example that could be replicated for 
modern breeding and synthetic biology. 
In order to ensure a balanced distribution of re-
search funds, we recommend introducing a pluralistic 
decision-making mechanism. The Swiss Agronomy Re-
search Board may provide a model example:27
“(1) The permanent Agronomy Research Board 
is appointed by the Federal Council and includes up to 
15 members. Stakeholders must be represented appro-
priately on the Agronomy Research Board, which in-
cludes representatives from among farmers, consumers 
and scientists.
 (2) The Board issues recommendations to the 
Federal Council on agronomic research and its long-term 
planning.”
Representatives from the field of environmen-
tal interests are however missing on the Board. None-
theless, the Confederation is legitimated to promote 
the cultivation of “ecologically valua-
ble crops” and the breeding of livestock 
that is “adapted to the country's natural 
conditions”.28
Public research institutes usu-
ally choose the subject matter and re-
search procedures for their R&D activi-
ties independently. However, these R&D 
activities are increasingly being used to 
serve governmental or private interests. As already men-
tioned, they are also increasingly pressed to patent their 
findings. This is an undesirable development. 
Funding for R&D in biotechnology should critically reflect its benefits and be 
accompanied by studies on the side effects on human health and the environ-
ment. We recommend that funding programmes should be developed involving 
representatives of environmental interests. Besides programme driven research, 
freely initiated research should continue to play a major role. Governmental and 
private priorities should not interfere with the principle of self-determination of 
research during selection and conduction of R&D activities. 
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27) Art. 117 Agricul-
ture Act (Federal  
Act of 29.4.1998 on 
Agriculture).
28) Art. 140 para. 1 
lit. a and art. 141 
para. 1 lit. a Agricul-
ture Act.
It is difficult to get a 
complete overview  
of the funding activities 
for research on genetic 
programmes.
Due to the very dynamic 
development of  
biotechnology, there  
is a risk that research 
funding and resear-
chers are lured into 
following fashion hypes.
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Regulation of the social benefits
In market economies, the value of a product is usually 
determined by the free interplay of supply and demand. 
State intervention is limited to protecting market players 
from unfair competition, e. g. by prohibiting misleading 
advertising or imposing labelling standards to ensure 
that consumers are provided with product information. 
However, with respect to specific products, the State is 
also responsible for quality controls. Public supervision 
is introduced when the quality of a product is crucial for 
the public interest, as with medicines for human use or 
pesticides for the protection of plants. 
Quality testing procedures have been developed 
for the use of genetic programmes in seeds and livestock. 
Quality standards ensure that farmers and the popula-
tion are provided with high quality material and suste-
nance respectively (Garbe 2012 no. 106). Quality testing 
procedures are organised in three steps: 
approval and registration of a novel va-
riety in the National Catalogue of Vari-
eties; recognition/certification of prop-
agated seeds of the approved variety; 
recommendation of specific varieties 
for cultivation. To be included in the 
National Catalogue of Varieties, a vari-
ety must meet the criteria of distinct-
ness, homogeneity and stability.29 These 
procedures are aimed at checking the 
benefits of varieties, though they focus 
on their industrial applicability more 
than on their inherent quality.30 A fur-
ther requirement is, however, that the 
variety “should prove more suitable for 
farming or use than the other exist-
ing varieties”.31 Compliance with this requirement is as-
sessed in cultivation tests.32 The examined parameters 
are: agronomic properties (e. g. stability, ripening period, 
security of yield in different weather conditions); resist-
ance to pests; productivity and product usability for dif-
ferent purposes (e. g. protein content, baking quality).33
We are undecided as to whether the above-men-
ioned criteria are primarily instrumental to protecting 
and increasing productivity, as well as to ensuring an ef-
ficient response to consumer expectations, or if they also 
reflect environmental concerns (e. g. the ability of the 
variety to achieve good yields also with a reduced use 
of plant-protection products, growth accelerators and 
chemical fertilisers). Environmental considerations do 
seem to be taken into account, insofar as the suitability of 
plants for cultivation and use in Switzerland is tested un-
der conditions of extensive farming, i. e. without any use 
of fungicides or growth regulators. This implies that the 
seeds can also be used in integrated production, with an 
optimised use of plant protection agents 
and fertilisers. In the past, an additional 
test was conducted in conditions of or-
ganic farming, i. e. with no use of herbi-
cides or commercial nitrogenous fertil-
isers. This test was suppressed after the 
evaluation of the results of plant varie-
ty examinations over a number of years 
showed that no clear differences could 
be detected in the ranking of varieties 
between the extensive farming and the 
organic farming trial network.34 How-
ever, it should be pointed out that in ad-
dition to the test under extensive farm-
ing conditions, a test under intensive 
farming conditions – including the use 
of fungicides and growth regulators – is 
also conducted in some cases and the final evaluation 
for variety recommendation combines both test results.35
We therefore recommend investigating the agro-ecological impact of the Swiss 
variety testing method more closely. As a preferred option, a comparative study 
should be conducted with selected EU countries. 
The Swiss testing system could prove, despite possible 
shortcomings, comparatively more developed from an 
environmental perspective. If this is true, Switzerland 
may not be ready to recognise the varieties in the EU 
Common Catalogue of varieties36 without further scruti-
ny.37 The non-specific and unambitious wording used in 
the formulation of the EU principle of “satisfactory value 
for cultivation” gives rise to concerns.38
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29) Art. 5 para. 1 
lit. a Ordinance on 
the production  
and marketing of 
vegetable propa- 
gating material 
(Verordnung vom 
7.12.1998 über die 
Produktion und das 
Inverkehrbringen 
von pflanzlichem  
Vermehrungs- 
material).
30) See how these 
three criteria are 
interpreted by the 
UPOV (2002).
31) Art. 5 para. 1 
lit. b Ordinance on 
the propagating 
material. In EU law, 
this corresponds to 
the criterion of 
satisfactory value for 
cultivation and use, 
see art. 4 para. 1  
and art. 5 para. 4 of 
Council Directive 
2002/53/EC on the 
common catalogue 
of varieties of agri-
cultural plant spe-
cies, OJ L 53, p. 2.
32) Directives of the 
Federal Office for 
Agriculture (FOAG) 
on the inclusion of 
varieties in the 
National Catalogue 
of Varieties Bern, 
July 2009.
33) Directive on 
seeds and seedlings 
of the Federal  
Department of 
Economic Affairs, 
Education and  
Research (EAER), 
Annex II. Testing  
is conducted by 
Agroscope.
34) Information 
provided by the 
Federal Office for 
Agriculture.
35) Federal Office for 
Agriculture (2008), 
p. 36.
36) Cf. Directive 
2002/53/EC.
37) Art. 5 para. 1 of 
the Agreement 
between the Euro-
pean Community 
and the Swiss  
Confederation on 
trade in agricultural 
products (Agricul-
ture Agreement)  
of 1.6.2002 as subse-
quently modified on 
1.6.2009.
38) See art. 5 para. 4 
Directive 2002/53/
EC: “The value of a 
variety for cultiva-
tion or use shall be 
regarded as satisfac-
tory if, compared to 
other varieties ac-
cepted in the cata-
logue of the Member 
State in question,  
its qualities, taken as 
a whole, offer, at 
least as far as pro-
duction in any given 
region is concerned, 
a clear improvement 
either for cultivation 
or as regards the 
uses which can be 
made of the crops or 
the products derived 
therefrom. Where 
other, superior 
characteristics are 
present, individual 
inferior characteris-
tics may be 
disregarded.”
The State conducts 
quality controls on 
pro ducts of public in-
terest (pharma ceuticals, 
pesticides, etc.).  
Tests on genetically 
manipulated seeds and 
livestock ensure  
that farmers are pro-
vided with high quality  
material and conse-
quently that the  
provision of sustenance 
to the population is 
guaranteed. 
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Cultivation recommendations also constitute an issue. 
Recommendations are based on an accurate assessment 
of information on varieties and are also tailored specifi-
cally to the geographical conditions of a country.39 Cul-
tivation recommendations for wheat in Switzerland, for 
example, include about 25 wheat varieties, out of a total 
of 4000 varieties inscribed in the Common Catalogue of 
varieties and the Swiss National Catalogue. These recom-
mendations are not officially mandatory, but farmers are 
indirectly pushed to comply with them if customers so 
require or product certificates use them as a reference, as 
in the case of the “Swiss Garantie” certificate of origin.
Since the great majority of farmers do follow the informal cultivation recom-
mendations, we recommend examining the actual purpose of the official cata-
logues of varieties. It might well be that their role as quality guarantors has 
been superseded by the more applied cultivation recommendations.
When analysing benefits, one should consider that varie-
ty approval procedures constitute a barrier to market en-
try that usually proves insurmountable for small farmers 
because of the associated costs for the provision of evi-
dence. This creates a de facto monopoly to the advantage 
of those seed producers that can afford to pay for the cost-
ly administrative approval procedure. At the same time, it 
also represents a threat to the diversity of native breeds, 
varieties and crops. A welcome change in this respect 
was the introduction of the so-called “approval for niche 
varieties” in Switzerland in 2010, exempting determinate 
seeds from meeting the requirements of distinctness, uni-
formity and stability. 40 
We recommend examining whether the niche approval for native breeds is serv-
ing its purpose or whether a further extension of approval opportunities should 
be provided for small-scale farming.
39) Cf. Hiltbrunner 
et al. (2014)
40) Art. 29 Ordi-
nance on seeds and 
seedlings of the 
Federal Departement 
of Economic Affairs, 
Education and Re-
search (Verordnung 
des WBF vom 
7.12.1998 über 
Saat- und Pflanzgut 
von Acker- und  
Futterpflanzen-  
sowie Gemüsearten).
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Regulating threats to health and the 
environment
Despite achieved benefits, R&D as well as economic ac-
tivities on genetic programmes may also pose risks to 
health and the environment. The proposed approach to 
genetic programmes does not imply that the risk analysis 
can be conducted at the molecular or cellular level only. 
Quite the opposite, as a change at this lower level has an 
impact also on higher levels such as the individual organ-
ism, populations and ecosystems. In fact, the interactions 
between the genetic level and several other factors occur-
ring at other levels should be taken into consideration.41
10.1 Risk control in genetic engineering, breeding and  
synthetic biology
So far, the strictest control system has been put in place 
for genetic engineering. This system is based on the 
Genetic Engineering Act that provides 
essentially the same level of protection 
ensured by the corresponding EU law. If 
not employed in closed systems, genet-
ically modified products are submitted 
to an accurate risk analysis before being 
released and marketed. 
Compared to genetically modi-
fied products, bred plants and animals 
are subject to fewer controls with re-
spect to the risks they pose to health 
and the environment, although breed-
ing methods are becoming increasingly 
invasive and their related risks are in-
creasing. For example, a rapeseed that 
has acquired insecticide characteristics, not through 
genetic engineering as defined by the law but rather 
through selective mutations, could transfer the gene 
responsible for this characteristic to wild varieties via 
pollination. Likewise, it might pose a risk to the health 
of consumers under certain conditions. 
The Environmental Protection Act sets 
out that organisms can be modified only 
if this does not cause adverse effects to 
the environment and human beings 
and upon condition that biodiversity is 
preserved,42 but the required risk as-
sessment is significantly less demand-
ing than controls imposed by the Ge-
netic Engineering Act. Similarly loose 
controls are imposed by variety approv-
al regulations, which set out that in ad-
dition to examining the distinctness, 
homogeneity and stability of a plant va-
riety, it should also be assessed wheth-
er such variety “proves more suitable for farming or use 
than the other existing varieties”.43
We therefore recommend extending the scope of the Genetic Engineering Act 
to the most invasive breeding methods, or improving the risk assessment re-
quirements for such methods in the existing environmental and variety approval 
legislation.44 Moreover, risk assessment models should be tailored to the spe-
cificities of selective breeding methods. A more detailed study is required on the 
state, benefits and risks of the new breeding methods that radically modify the 
genome.
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41) See the example 
of Bt-Mais and the 
risk analysis by 
Breckling/Böck-
mann/Reuter (2012).
42) Art. 29 a Envi-
ronmental Protec-
tion Act (Federal  
Act of 7.10.1983 on 
the Protection of 
Environment)
43) Art. 5 para. 1 
Ordinance on the 
propagating material
44) Cf. the study 
conducted by the 
Canton of Zurich 
upon commission of 
the Federal Office for 
the Environment 
(2012) “Grundlagen 
für die Klärung 
offener Fragen bei 
der rechtlichen 
Regulierung neuer 
Pflanzenzuchtver-
fahren”.
Surprisingly, bred  
varieties and animals 
are subject to fewer 
controls with respect 
to the risks they  
pose to health and the 
environment in  
comparison to geneti-
cally modified  
organisms, although 
breeding methods  
are becoming increas-
ingly invasive.
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The need might arise to extend the scope 
of the Genetic Engineering Act also to 
synthetic biology. As mentioned before, 
the Genetic Engineering Act deals with 
modifications in organisms. Synthetic bi-
ology works differently, because it reduc-
es the source organism to a minimal life- 
sustaining cell that becomes a chassis 
into which an artificial system of mod-
ular genes is integrated. Certainly, this 
technology cannot be said to modify an 
organism, as it is becoming increasing-
ly oriented towards the creation of nov-
el organisms. The novel organism is not 
designed by nature but at the computer, 
and instead of being constituted by the 
available genes, it is generally synthe-
sised chemically.45
The risks posed by synthetic biology 
have barely been identified and exam-
ined. Because of the increasing artifici-
ality of the produced formations, it is of-
ten assumed that they can only survive 
and reproduce, if ever, in artificial con-
ditions. This “orthogonality”, i. e. total extraneousness 
to natural conditions, is especially pronounced in xeno-
biology, which goes so far as to replace the four basic 
components of DNA. However, it should not be excluded 
that some products obtained through these technologies 
might interact with the environment and cause damage. 
It is therefore questionable, that the Swiss Academies of 
natural and engineering sciences should deem it neces-
sary to take measures only in 5 to 10 years' time.46 By 
then, path dependencies may have already been estab-
lished which, we believe, might pose an obstacle to an 
objective and detailed risk analysis.
We recommend starting studies on the lines of research in synthetic biology 
that are most likely to pose risks to human beings or the environment, with a 
view to including them in the scope of the Genetic Engineering Act.
Should these lines of research be made 
to fall under the scope of the Genetic 
Engineering Act, questions may arise as 
to whether the currently used risk as-
sessment methods are suitable to assess 
the risks posed by synthetic biology. The 
answer should be no: when this disci-
pline works within closed systems, risk 
classes and confinement systems should 
be gauged accordingly. A totally new as-
sessment approach must be developed for 
any instance that includes an output in 
the environment. Traditionally, the core 
criterion for genetic engineering risk assessment has been 
familiarity, i. e. the risks of genetic modified organisms 
(GMO) are usually derived from the risks of the paren-
tal organisms (the donating and the recipient organism). 
It is generally assumed that the risks of 
the derived organism are small when the 
risks of the parental organisms are small 
too. The application of this criterion to 
genetic engineering is controversial, as 
it proceeds merely on the basis of addi-
tion and neglects the dynamics ensuing 
from the combination of foreign genes. 
And it is completely unsuitable for syn-
thetic biology, where the importance of 
parental organisms is reduced to a mini-
mum or even totally suppressed (Winter, 
to be published). The potential risks that 
are most likely to occur and need to be examined more 
closely might be inferred from the characteristics of the 
minimal cell, the modular bioparts it incorporates and 
the system design of the novel organism.
We recommend developing new risk assessment methods that are specific to 
synthetic biology. Such methods should identify appropriate tests to be con-
ducted on the produced organisms. 
45) See the detai led 
and non-academic 
explanation by 
Baldwin et al. 
(2012).
46) See Swiss  
Academy of Sciences 
and Swiss Academy 
of Engineering 
Sciences (2010), 
p. 22. An opinion  
in favor of a concur-
rent risk analysis 
was expressed by 
the Federal Ethics  
Committee on 
Non-Human Biotech-
nology in its 2010 
report. 
The Genetic Engineering 
Act regulates the  
modification of  
organisms and not their 
creation.
It should not be  
excluded that products 
of the synthetic  
biology, which are  
supposed to live only in 
artificial environment, 
might interact  
with the natural  
environment and cause 
damage. 
Traditionally, the  
core criterion  
for genetic engineering 
risk assessment has 
been familiarity.  
This criterion will be 
unsuitable if, like in 
case of products  
of the synthetic biolo-
gy, the relevance  
of the parent organ-
isms is minimized. 
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10.2 Evaluation of residual risks and benefits
Another issue that concerns all biotechnologies consid-
ered here is the risk assessment stage. As a rule, the result 
of risk assessments is that the risk cannot be ruled out 
altogether, although the hazard is usually rated to be “un-
certain”, “unlikely”, with “low likelihood”, “negligible”, 
etc.47 The wording used warns us that the evaluation in 
the risk analysis requires closer scrutiny. The risk assess-
ment should contain at least some mention of the fact that 
the tested organism also provides some benefits; were this 
not the case, it would not make sense to accept an even 
remotely likely hazard. However, as a rule these benefits 
are not explicitly described and supported by evidence. 
A description of the benefits should be demanded, as the 
effects of GMOs on the environment are highly complex 
and there will always be a certain degree of uncertainty, 
which should not be tolerated unless the GMO generates 
a measurable benefit. 
Whenever a risk assessment comes to the conclusion that the remaining risk is 
uncertain, unlikely or negligible, we recommend requesting that the usefulness 
of the organism examined also be described and justified in detail. 
An agronomic and ecologic benefit would be acceptable, 
such as the reduction of artificial fertilizers and chemical 
plant protection products (v. Kries/Winter 2011). It re-
mains to be seen whether the two main lines of develop-
ment in the genetic engineering of plants – resistance to 
insects and herbicides48 – really do provide such benefit: 
pest resistance can result in pests developing immunity, 
while herbicide resistance incentivizes the use of larg-
er quantities of herbicides in addition to combining two 
environmental hazards, namely genetic modification and 
the use of chemicals (Then 2014). An alternative could 
be found in some kind of “soft genetic engineering” that 
fits into the agricultural and environmental cycles; in the 
example of herbicide resistance, soft genetic engineering 
should not confer the plant the ability to survive chemical 
herbicides, but rather provide it with a growth advantage 
over the weeds.
47) See the formula-
tion in Scientific 
Opinion on applica-
tion (EFSA-GMO-
CZ-2008-54) for 
placing on the mar-
ket of genetically 
modified insect 
resistant and herbi-
cide tolerant maize 
MON 88017 for 
cultivation under 
Regulation (EC) Nº 
1829/2003 from 
Monsanto, EFSA 
Journal 2011: “The 
EFSA GMO Panel 
concludes that po-
tential adverse 
effects of maize 
MON 88017 due to 
the expression of the 
Cry3Bb1 protein to 
non-target terrestrial 
(plant- and ground- 
dwelling), soil and 
aquatic arthropods 
are expected to  
be negligible in the 
context of its pro-
posed uses.”  
“If subjected to 
appropriate manage-
ment measures,  
the cultivation 
management of 
maize MON 88017 
is unlikely to raise 
safety concerns for 
the environment.” 
“Moreover, scientific 
uncertainty related 
to the appropriate-
ness of the ‘high 
dose/refuge strate-
gy’ in delaying 
resistance evolution 
in Western corn 
rootworm remains.”
48) Insect resistance 
means that the plant 
releases an insect- 
killing poison, while 
herbicide resistance 
means that the plant 
is insensitive to 
some noxious sub- 
stances. 
30
10.3 Coexistence of genetically modified crops  
with GMO-free farming
Although they do not necessarily constitute a direct 
health and environmental hazard, genetically modified 
organisms released into the environment can cause eco-
nomic damage when transgenes – i. e. genes taken from 
other species – are transferred by pollination to neigh-
bouring fields cultivated with the same crops. When 
this happens, farmers from the neighbouring fields are 
no longer able to market their crops as GMO-free, and if 
the modified crop variety has not been approved yet, they 
can find themselves in the position of having to apply for 
a marketing authorisation pursuant to the Genetic Engi-
neering Act because of the presence of genetically mod-
ified units in the harvest.49 Some countries have tried to 
address the issue with coexistence regulations. Generally, 
these regulations prescribe that a certain distance must 
be maintained between GMO fields and fields cultivated 
with standard crops. The coexistence regulations are also 
discussed in Switzerland.50 However, this solution relies 
on reconcilement between diverging individual farmers 
and may give rise to conflicts at a local level.51 These con-
flicts could be reduced minimized by determination of 
whole areas with or without GMOs, whereby the determi-
nation could be achieved through voluntary agreements 
or spatial planning regulations, such as Landscape plans, 
space planning instructions or future agronomic plans. 
The conclusion of voluntary agreements for the coexistence of GMO and GMO-
free farming through the creation of GMO-free areas should be encouraged. 
Additionally, we recommend considering spatial planning solutions. 
Such planning instruments raise some concerns with re-
spect to their compatibility with the free-trade principles 
of EU and WTO regulations. Ultimately, such objections 
can be set aside, because planning does not interfere 
with the marketing of genetically modified products; it 
merely regulates their use and is objective-
ly required to ensure coexistence between 
opposite farming methods (Epiney 2011). 
The strategy of coexistence could 
prove a way to prevent the economic dis-
advantages of genetic engineering from 
impacting on GMO-free farmers. Howev-
er, this strategy cannot be ecologically ef-
fective in the long term for two reasons: 
first, organisms obviously do not comply 
with crop separation rules and second, coexistence en-
tails significant costs for GMO farming both during cul-
tivation and in the processing and supply chain. In other 
words, there is no way out of the fundamental dilem-
ma on whether and how the release and marketing of 
GMOs should be authorized. The rec-
ommendation above is thus further 
corroborated: besides considering 
risk minimisation, a motivation illus-
trating the advantages derived from 
GMOs should also be provided and a 
“soft” version of genetic engineering 
should be adopted (Winter 2011).
49) According to the 
case law of German 
courts, see VG  
Augsburg, sentence 
of 29.3.2011 (Az. Au 
1 K 10.947).
50) Cf. draft of an 
Ordinance consider-
ing measures in the 
agriculture sector  
for coexistence of 
genetically modified 
plants and non-modi-
fied plants (Gen-
technik-Koexistenz-
Verordnung, KoexV, 
30.1.2013). During 
the consultation 
process, a large 
majority of the in- 
volved stakeholders 
generally argued 
against GMO farm-
ing in Switzerland. 
On the basis of this 
feedback, the  
Federal Offices for 
the Environment 
and Agriculture 
developed new 
options that were 
discussed with the 
involved parties 
during workshops 
held in June and  
July 2014.
51) See also the draft 
proposal for an 
amendment to the 
Genetic Engineering 
Act of 30.1.2013, 
which provides two 
models for the estab-
lishment of “GMO-
free farming areas”: 
either the cantonal 
authority designates 
an area as GMO-free 
upon request of a 
voluntarily estab-
lished entity, or the 
designation is made 
upon the Canton’s 
own motion and  
the cantonal authori-
ty also appoints a 
competent body (cf. 
Art. 19e of the draft 
proposal). Also this 
draft proposal was 
included in the  
mentioned consult- 
ation.
Since the coexistence of 
GMO and GMO-free 
farming has proven  
to be ineffective and  
economically  
unsustainable, the 
question arises as  
to what criteria should  
be used to judge 
whether and how the 
release of GMOs should 
be authorized.
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10.4 Should foreign investments be subject to control?
Looking at Switzerland, if one adds up to the domestic 
use of genetic programmes their use on the part of Swiss 
enterprises globally, the resulting potential is huge in 
comparison to the size of the country. The leading sec-
tors are seed production and the pharmaceutical indus-
try. Swiss corporations operating in these sectors have 
set up a broad global network of foreign subsidiaries that 
are responsible for R&D and the production of market-
able products. For example, Syngenta controls 9 % of the 
global commercial seeds market, ranking third behind 
Monsanto (27 %) and Du Pont (Pioneer) (17 %).52 Markets 
are supplied both through exports and through direct 
foreign investments. 
The foreign but Swiss-controlled production of 
genetically modified organisms can result in paradoxi-
cal situations. For instance, Syngenta has applied to the 
European Commission for authorisation to import and 
market a maize variety for food and 
feed uses containing five genetic mod-
ifications.53 However, Syngenta did not 
apply for a cultivation permit. The most 
likely explanation is that Syngenta is 
aware that the cultivation of GMOs in 
the EU and in Switzerland meets with 
public opposition because of the poten-
tial environmental risks (e. g. damage 
to non-target organisms) or contami-
nation of other maize fields cultivated 
with conventional or organic methods. 
Hence, Syngenta prefers to apply for and 
obtain cultivation permits in other countries, where no 
such public concerns are expressed.54 As a result, the 
modified maize variety will be cultivated in countries 
that impose less strict conditions for its subsequent im-
portation into the EU – and Switzerland, if Swiss author-
ities lean their market authorisation on that of the EU. 
The question is whether Switzerland 
should oblige companies based in its ter-
ritory to comply with Swiss regulations 
in their direct foreign investments.
This could be legally objec-
tionable and contrary to the principle 
of territoriality,55 according to which 
the laws of the recipient country gov-
ern direct investments. However, terri-
toriality is no longer understood as an 
absolute principle; it is not considered 
to be violated if activities abroad have 
effects on the home country (Müller/
Wildhaber 2001, p. 398 et seqq). Its relativity is especial-
ly apparent in environmental law and in 
its scope, which is acquiring an increas-
ingly transnational dimension because 
natural processes abroad are interrelat-
ed with national ones and because envi-
ronmental impacts in one country can 
have repercussions in another coun-
try. Let us suppose, by way of example, 
that traditional farming in Latin Ameri-
ca were replaced by large plantations of 
soya beans, eucalyptus and the like be-
cause of cultivation of GM plants: the 
resulting effects on the global climate 
would backfire against the investor countries. These ef-
fects would also affect Switzerland and therefore allow 
introducing counteractive measures.
52) Berne  
Declaration (2014a)
53) Application for 
authorization of 
genetically modified 
Bt11 x 59122 x 
MIR604 x 1507 x 
GA21 maize for food 
and feed uses,  
import and process-
ing submitted under 
Regulation (EC)  
Nº 1829/2003 by 
Syngenta (EFSA- 
GMO-DE-2011-99).
54) Cf. Berne  
Declaration (2014b) 
p. 22 et seqq. 
55) According to  
the territoriality 
principle, the juris-
diction of a State 
(including its  
legislation, adminis-
tration and case  
law) only extends 
over that country's 
territory.
Seed production and 
pharma multinatio- 
nals seated in Switzer-
land have set up a 
broad global network 
of foreign subsidiaries 
that are respon- 
sible for the develop-
ment and the  
production of marke-
table products.
Genetically modified 
seeds can be cultivated 
in countries that  
impose less strict  
conditions and are then 
imported into the EU – 
and Switzerland, if 
Swiss authorities  
lean their market  
authorisation on that of 
the EU.
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10.5 Should the production of imported products be  
subject to controls?
A related question is whether Swiss law should also reg-
ulate the production methods for imported products even 
when Swiss companies do not control their production. 
To that end, a control could be exerted 
through the domestic pull of demand 
for such products (so-called process and 
production measures or ppm, in the ter-
minology of international trade law). 
Controls may include verifying wheth-
er imported products obtained with the 
use of biotechnologies have caused en-
vironmental damage in the country of 
origin during the production phase. A 
less obtrusive control would consist in 
verifying whether the imported item 
was produced in the exporting coun-
try in compliance with the locally valid regulations. The 
EU regulation on timber imports sets an example here.56 
From the legal point of view, a compliance control can be 
conducted on the importer's obligation of due diligence. 
In practice, the lawfulness of the tree harvesting activity 
is not actually verified. Alternatively, the importing coun-
try could impose its own standards, making up for any 
substandard requirements in force in the 
exporting country. An example of this is 
the EU regulation on biomass imports.57 
Another example is provided by 
the case of hormones in meat. The EU 
import ban on beef from animals treat-
ed with growth-promoting hormones 
was judged in the WTO dispute settle-
ment procedure only in relation to the 
possible presence of hormone residues 
in meat that is liable to pose a health 
risk for consumers.58 The underlying is-
sue is that the breeding method used for 
the cattle is inappropriate for the species. Interestingly, 
this consideration was not made in the settlement proce-
dure, although it would have been appropriate to address 
this aspect as well.
We suggest starting a political debate on this topic and exploring through stud-
ies whether it would be advisable to incorporate production standards in import 
regulations for biotechnical products. 
56) EU regulation 
no. 995/2010 of the 
European Parliament 
and of the Council  
of 20.10.2010 laying 
down the obligations 
of operators who 
place timber and 
timber products on 
the market, OJ L 295 
p. 23, articles 4–6. 
57) Directive 
2009/28/EC of the 
European Parliament 
and of the Council  
of 23.4.2009 on the 
promotion of the use 
of energy from 
renewable sources, 
OJ 2009 L 140,  
p. 16, Art. 17.  
No import bans are 
imposed on the basis 
of this directive. 
Rather, its aim is to 
exclude imported 
products from the 
calculation of each 
Member State's 
target of energy gene- 
ration from renewa-
ble sources. 
58) WTO Appellate 
Body, EC Measures 
Concerning Meat 
and Meat Products 
(Hormones), WT/
DS26/AB/R and 
WT/DS48/AB/R.
When importing bio-
technical products, 
their production  
process in the country 
of origin could be  
verified in order to see 
if it has caused any 
environmental damage 
or at least if the legal 
provisions in force  
have been observed.
33
Cultural factors
Traditionally, risk regulation has concentrated on the pro-
tection of human health and the environment. Animal 
welfare has been considered too. The discussion on ge-
netic engineering shows that citizens also have other con-
cerns linked to what can be described collectively as “cul-
tural typifications” or “cultural patterns” (Schütz 1972). 
These concerns originate from a number of assumptions 
that may vary significantly from country to country as 
they depend essentially on the historical development of 
each civilisation. Concerns are expressed about five as-
pects in particular: 
• Doubts about the usefulness of technology, based on 
the belief that nature already contains all desirable 
organisms.
• Heightened apprehension for health and environmen-
tal hazards.
• Trust in the long experience of evolution compared to 
the partial and limited time horizon of biotechnologi-
cal tests.
• Beliefs about the integrity of living beings.
• Ethical and religious concerns for a man-made hybrid 
versus Nature and Creation.59
Probably, cultural typifications will also extend to syn-
thetic biology and highly artificial breeding, as soon as 
the public becomes more aware of their existence. 
Cultural typifications play a significant role in 
democracies. They can trigger political demonstrations, 
e. g. against the release of genetically modified organ-
isms (GMOs) into the environment, and influence the 
preferences of consumers, who tend to choose non-mod-
ified products. Despite their undeniable importance, 
they are totally disregarded in risk 
regulations. Only a few States have 
attempted to take this factor into ac-
count. Reasons of public morality are 
usually recognised, as in art. 4 para. 4 
of the Swiss Law on technical barriers 
to trade.60 In article 8 of the Swiss Ge-
netic Engineering Act, the dignity of 
the living being is set as a standard: “Engineered mod-
ifications of the genetic material of animals and plants 
must not violate the dignity of the living being. Their 
dignity is deemed to have been violated when charac-
teristics, functions or ways of liv-
ing that are specific to that species 
are significantly compromised if 
this is not justifiable by preponder-
ant interests worthy of protection. 
The damage caused to animals 
and the damage caused to plants 
must be assessed differently from 
each other.”
This clause is clearly lim-
ited to the ethical aspect. More-
over, it leaves the door open to 
trade-offs that are contrary to the deontological61 con-
cept of dignity. A more comprehensive definition is pro-
vided in art. 10 of the Norwegian Genetic Engineering 
Act: “In deciding whether or not to grant an application, 
considerable weight shall also be given to whether the 
deliberate release will be of benefit to society and is like-
ly to promote sustainable development.”
So far, this declaration of principle has however 
had no practical effects. Decisions are usually based on 
the assessment of health and environmental risks (Spök 
2012). Since such risks have been assumed in Switzer-
land, the need has not yet arisen to resort to the cultur-
al factor.
Concerningly, the WTO system has proven to be 
completely insensitive to the cultural factor, especially in 
the agreements on Sanitary and Phy-
tosanitary Measures (SPS) und Techni-
cal Barriers to Trade (TBT) that are rel-
evant in the present context. The case 
law that applies to these agreements 
recognises health and environmental 
protection as legitimate reasons to lim-
it trade. In the case “EC – Measures Affecting the Ap-
proval and Marketing of Biotech Products”,62 the panel 
did not mention once in its about 1000-page delibera-
tions that the EU moratorium was essentially motivated 
by cultural typifications. 
We recommend that Switzerland examine the role of cultural typifications more 
closely and include them in its regulatory framework on the use of genetic 
programmes in biotechnologies.
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59) For a detailed 
analysis of these 
concerns see the 
report of the Federal 
Ethics Committee  
on Non-Human 
Biotechnology (2010).
60) See also art. XX 
GATT.
61) Deontology or 
value ethics judges 
actions on the basis 
of values. In this 
respect, it differs 
from consequential 
ethics (ethics of res- 
ponsibility), which 
judges actions on the 
basis of their effects 
(for example in 
terms of costs and 
benefits). Cf. Federal 
Ethics Committee  
on Non-Human 
Biotechnology (2010).
62) European  
Communities – 
Measures Affecting 
the Approval and 
Marketing of Biotech 
Products, Panel 
Report WT/DS 291, 
292, 293/R 29, 
19.9.2006.
Traditionally, risk  
regulation has  
concentrated on  
the protection of  
human health and the 
environment. 
Genetic engineering 
issues show that  
citizens have – besides 
the protection of 
health and environment – 
further concerns that 
are influenced by  
what can be described 
collectively as  
“cultural typifications”.
Despite their practical 
importance, cultural 
typifications are  
totally disregarded in 
risk regulations.
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Cultural typifications could be taken 
into account through product identifi-
cation rather than through binding reg-
ulations. Both Switzerland and the EU 
have opted for the mandatory labelling 
of genetically modified foods. However, 
identification requirements apply only to 
foodstuffs that contain genetically modified cells or are 
produced from GMOs, such as milk obtained from ge-
netically modified cows.63 No labelling obligations exist 
for foods containing or consisting of organisms fed with 
genetically modified feeds, e. g. pigs fed 
with genetically modified soya. In theo-
ry, genetically modified feeds can be im-
ported64 to be used in industrial animal 
fattening processes. As long as farmers 
in Switzerland abstain from genetically 
modified feeds they are in concurrence 
with imported products that may produce at a lower price 
without this restriction. The freedom of choice for con-
sumers is limited if the conditions of feeding are not sub-
ject of labels.
We propose that Switzerland also prescribe the identification of foods obtained 
from the processing of animals fed with genetically modified feeds.65
The indication of opposite characteristics, i. e. the absence 
of genetic modifications in a product, is also a topic open 
for discussion. The EU does not have any such label. 
However, the absence of genetic modifications is implied 
through other labels, in particular those provided on 
organic products. Unlike the EU, Switzerland has intro-
duced provisions for the labelling of products “containing 
no genetic modifications” with very strict evidence-based 
requirements that have limited its use in practice.66
63) Art. 7 FDHA 
Ordinance on  
genetically modified 
foodstuffs (Verord-
nung des EDI vom 
23.11.2005 über 
gentechnisch 
veränderte Lebens-
mittel); Art. 12 EC 
Reg. 1829/03.
64) The commercial-
ization needs a per- 
mission, cf. Art. 12 
Swiss Law on genet-
ic engineering.  
In the EU modified 
feeds must be indi-
cated in labels, see 
art. 24 EC Reg. 
1829/03. 
65) The Ordinance 
on genetically modi-
fied foodstuffs is 
currently being 
revised to cover also 
this aspect. The 
consultation on the 
revised wording of 
the law was conclud-
ed on 31.3.2014. 
66) Cf. Art. 7 para. 8 
Ordinance for genet-
ically modified food.
Instead of using  
regulations, product 
labelling could  
be a way of taking  
cultural typifications 
into account.
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Sharing the benefits arising from the 
utilisation of genetic programmes
The benefits obtained from the utilisation of genetic pro-
grammes developed by R&D activities are essentially 
reaped by the subjects entitled to claim 
exclusive rights on them. In the chapter 
on sovereignty and property rights, we 
explained that all genetic programmes 
available in Switzerland whether in situ 
(i. e. in natural habitats), ex-situ (i. e. in 
botanical gardens and other plant col-
lections), or created in laboratories, fall 
under the Swiss jurisdiction. Under 
the current Swiss legislation, these ge-
netic programmes are considered to be 
non-ownable by the national law. Foreign and Swiss re-
searchers can use, modify and re-combine this genetic 
material at will. The benefits arising from this need not 
be shared with the Swiss State. If intellectual property 
rights are established for this material, however, its ge-
netic modification or recombination may be subject to 
the approval of the right-owner, who may, under certain 
conditions, be entitled to a share of the benefits.
Swiss law does not prescribe a regime controlling 
the access to genetic material, but the Federal Council 
has the power to introduce access restrictions if it so de-
cides.67 Out of all industrialised countries, only Austral-
ia and Norway have implemented access policies. The 
EU provides no harmonisation on this matter, which 
is therefore individually ruled by each single Member 
State. For instance, no regulation is planned to be in-
troduced in Germany. In fact, several arguments speak 
against an access regime that could 
end up imposing a huge administra-
tive burden on the otherwise unham-
pered research and development ac-
tivities. Switzerland itself would have 
to survey in its own country but also 
abroad the whole process from drawing 
the sample over different steps of R&D 
until the marketable product or intellec-
tual property rights. Furthermore, the 
potential financial return would proba-
bly be minimal. Although monetary compensations have 
been envisaged since the implemen-
tation of the CBD in 1993, they have 
hardly ever been paid anywhere in 
the world. In any case, the transaction 
costs would probably be higher than 
the potential returns in the long term. 
Benefits deriving from cooperation in 
research and development would be 
more meaningful than monetary ben-
efits. To reap such non-monetary ben-
efits is currently at the centre of the 
international debate on benefit sharing 
(Kamau/Winter 2013). 
Following these considerations, we discourage the Federal Council from using 
its legislative powers to introduce provisions regulating the access to genetic 
resources.
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67) Art. 23 q para. 1 
of the Federal Act of 
1.7.1966 on the 
Protection of Nature 
and Cultural Herit-
age: “The Federal 
Council has the 
power to subordi-
nate the access to 
domestic genetic 
resources to a notifi-
cation or permit,  
as well as to an 
arrangement on the 
use of genetic re-
sources and the 
distribution of the 
ensuing benefits.”
A regime controlling 
the access to the  
genetic material would 
impose huge  
administrative burdens 
and stifle research  
and development  
activities. Furthermore, 
the potential finan- 
cial return would prob-
ably be minimal.
The benefits arising 
from the utilisation  
of genetic programmes 
developed by R&D  
activities are essential-
ly reaped by the  
subjects entitled to 
claim exclusive rights 
on them.
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The issue of benefit distribution does 
not apply solely to the benefits of ge-
netic programmes available in Switzer-
land, but also to the genetic resources 
that originate from another country 
and have been transferred to Switzer-
land, where they are used in R&D ac-
tivities. Provided that these are genetic 
resources under the CBD and that they 
have been found and taken in situ and 
ex situ, the Provider State is authorised, 
as mentioned in the chapter on ownership, to impose ac-
cess regulations and to demand a share of the benefits.68
On the side of the User States, specific controls envisaged 
in the Nagoya Protocol must be introduced. User States 
have the obligation to ensure that the genetic resources 
used in their territory for R&D processes have been ex-
tracted and exported in compliance with the access reg-
ulations of the Provider States and that mutually agreed 
terms (MATs) are in force to ensure sharing of benefits.69 
Furthermore, User States must provide access to justice 
and other institutions to ensure the enforcement of the 
agreed terms.70 In the law transposing 
the Nagoya Protocol, Switzerland formu-
lated the following provisions:71
“Art. 23 n Due diligence requirement
(1) Any person who – according to the 
Nagoya Protocol – utilises genetic re-
sources or directly benefits from their 
utilisation (Users) shall apply due dili-
gence appropriate to the circumstances 
to ensure that:
a.  the resources have been accessed lawfully; and
b.  mutually agreed terms are in force for the purpose of 
achieving a fair and equitable sharing of the benefits 
obtained.
Art. 23 o Notification requirement
Compliance with the due diligence requirement must be 
notified to the Federal Office for the Environment FOEN 
before market authorisation has been obtained or, if such 
authorisation is not required, before the commercialisa-
tion of products developed on the basis of utilised genetic 
resources.
Art. 24  a 
(1) …
(2) Any person who intentionally fails to provide informa-
tion or provides false information under article 23 o shall 
be liable to a fine of up to CHF 100 000; if the offender acts 
through negligence, the fine shall be up to CHF 40 000.”
The obligation of the researcher or developer (“User”) is 
thus limited to compliance with the access requirements 
of the Provider State. A self-standing benefit sharing re-
quirement had been proposed in the draft version of the 
law,72 but no mention of it is contained in the final text. 
This omission is regrettable, because 
Switzerland could have gone beyond a 
minimalist interpretation of the Nagoya 
Protocol, setting a good example and 
winning over the trust of the Provider 
States. 
68) Art. 15 CBD and 
art. 5 and 6 Nagoya 
Protocol. The latter 
has been ratified  
and enforced by 
50 States. Switzer-
land ratified the 
Nagoya Protocol on 
11.7.2014 and trans-
posed its provisions 
in the Nature and 
Cultural Heritage 
Protection Act. 
69) Art. 15 Nagoya 
Protocol.
70) Art. 18 Nagoya 
Protocol.
71) Art. 23 n and 23 o 
of the Federal Act on 
the Protection of 
Nature and Cultural 
Heritage. Useful 
guidelines for re-
searchers are provid-
ed in: "Access and 
Benefit Sharing. 
Good practice for 
academic research  
on genetic resources" 
Swiss Academy of 
Sciences, 2006  
(by S. Biber-Klemm 
and S. Martinez).  
See also the template 
of the "Agreement  
on Access and Benefit 
Sharing for Non-Com- 
mercial Research. 
Sector specific ap-
proach containing 
Model Clauses", 
Swiss Academy of 
Sciences, 2010  
(by S. Biber-Klemm,  
S. Marinez, A. Jacob, 
A. Jevtic).
72) Under article 23 n 
of the draft version, 
Users shall "apply 
due diligence appro-
priate to the circum-
stances to ensure 
that […] b. these 
benefits are shared in 
a fair and equitable 
way." The draft 
version is available in 
English under www.
cbd.int/abs/doc/
SwissRatification_of_
the_NP-Draft_legal_
measures-10_
April_2013.pdf
The issue of benefit 
distribution does not 
apply solely to the  
domestic genetic  
programmes, but also 
to the genetic  
resources that have 
been transferred to 
Switzerland, where they 
are subject to R&D. 
Under the Nagoya  
Protocol, anyone using 
genetic resources  
or deriving direct bene-
fits from their  
utilisation must ensure 
that such genetic  
resources have been 
accessed lawfully.
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It is also questionable, that the authori-
ties are required to be notified of compli-
ance with the due diligence requirement 
rather late, when the product based on 
genetic resources is marketed, and that 
only the violation of the notification re-
quirement is sanctioned with a fine. This 
implies that the entire research and de-
velopment process on genetic resourc-
es is devoid of controls. This cannot be 
possibly reconciled with the Nagoya 
Protocol. Art. 15 para. 1 and art. 18 
of the Protocol demand that the User 
States must monitor the utilisation of genetic resources 
for their research and further development in order to 
make sure that the requirements set by 
the Provider States are met. A critical 
issue is to establish how the “benefits 
resulting from the utilisation of genetic 
resources”73 can be determined. A very 
long time can elapse before a genetic pro-
gramme is valorised. In the valorisation 
process, there might be steps between 
the access to the biological material and 
the marketing of the final product, in 
which the information on the genetic 
resource becomes public domain (e. g. is 
available in databases accessible to the 
public). Public domain information can thus be used for 
privately held knowledge and products. 
We recommend examining more closely whether Switzerland as a User State is 
obliged and in a position to prescribe that the databases domiciled in its terri-
tory should ensure traceability of information to the State that has provided the 
source organism and comply with the access conditions valid in that State. 
When determining the benefits, another aspect to consid-
er is that the Provider State's sovereign rights may volatil-
ise during the valorisation process. This may happen, for 
instance, when the genetic programme is used only for 
comparison with another programme in order to better 
identify the latter and in the end the latter and not the 
former is used for product development. 
We recommend studying in greater detail how the entitlement to the sharing of 
benefits obtained from genetic resources may be exhausted in the R&D process. 
Given the difficulty in determining the benefits obtained 
from the use of genetic resources (Kamau/Winter 2013), 
more thorough reflection is needed on the possible 
alternatives to the “benefit-sharing in exchange for ac-
cess” approach proposed in the Nagoya Protocol.
We suggest considering a number of multilateral approaches to the sharing of 
benefits from the utilisation of genetic resources – from cooperation on re-
search to material and data pools through to financial funds. Switzerland could 
give its original contribution to the forthcoming international negotiations, thus 
taking its pioneering role in the development of bilateral contractual solutions 
one step further. 
73) Art. 1 dbis of the 
Federal Act on the 
Protection of Nature 
and Cultural Herit- 
age.
The authorities are  
required to be notified 
of compliance with  
the due diligence  
requirement only at the 
marketing stage.  
This implies that the 
entire research  
and development  
process on genetic re-
sources is devoid of 
controls. 
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Summary
Most of the time, the different biotechnical utilisations of 
genetic programmes are discussed in separate fora, and so 
is their legal regulation. An overall view is needed here 
to consider systematically both the different utilisations 
and their various legal implications. This overview should 
help finding common denominators in the developments 
and challenges in the field of utilisations in order to set the 
goals for a sustainable management of genetic resources. 
Conclusions and recommendations
A change in perspective from phenotype to genotype can 
be observed in science, technology, economics and law. 
The implications of this change for Switzerland have not 
been thoroughly elaborated yet. Our suggestion is to re-
search its effects more accurately and to analyse its po-
litical impact.
The term “genetic resources”, introduced by 
the Convention on Biological Diversity, is not sufficient 
in this context because it does not include artificial se-
quences. We suggest using the broader term “genetic 
programmes”, so that the products of synthetic biolo-
gy are also included. The following definition of genetic 
programmes is provided: a genetic programme is made 
of DNA and RNA sequences that have been either gen-
erated naturally or assembled artificially. It is normally 
found in cells or incorporated into them, but can also be 
produced and used separately at a subcellular level.
Modern breeding methods have such a depth 
of intervention that they cast doubts on the validity 
of the legal demarcation between breeding and genet-
ic engineering. We therefore recommend rethinking 
the boundaries between the two. The same applies to 
synthetic biology: since synthetic biology radically re-
designs existing organisms, it also needs to be demar-
cated and differentiated from genetic engineering. Fur-
thermore, we also recommend examining in detail the 
current lines of research in biotechnology that are being 
followed in Switzerland in order to verify whether they 
really provide the best opportunities for the acquisition 
of knowledge and its utilisation, or whether other lines 
of research should be developed.
The political debate and decision-making on the 
utilisation of genetic programmes in Switzerland should 
be based on a clear idea of the extent to which the devel-
opment of genetic programmes should be privatised and 
research activities should make their findings available 
to the public domain. We recommend making the re-
sults of basic research on genetic programmes available, 
to the maximum extent possible, to the public domain. 
Still, provisions should be taken to make sure that the 
costs for the unbiased and lasting storage and availabili-
ty of such information are covered.
We suggest that national and cross-border col-
lections, exchange networks, and research and devel-
opment activities concerning genetic programmes in 
Switzerland be included in a separate study and evaluat-
ed in terms of their performance and costs.
Our opinion is that discoveries about genetic programmes 
should be understood as improvements to the common 
knowledge of society. We therefore recommend that Swit-
zerland should vote against the patentability of discover-
ies in international negotiations. Patents are admissible 
only in the later stages of the valorisation process of ge-
netic programmes.
Intellectual property rights owners are progres-
sively taking possession of living nature, thereby ac-
celerating an ongoing industrialisaton of farming with 
critical social and environmental consequences. We rec-
ommend exploring ways of limiting patentability in the 
plant and animal domains.
Funding for research activities on genetic pro-
grammes should be objectively linked to the bene-
fits that can be derived from these projects and pro-
grammes. Money should be assigned only to research 
projects that also explore the side-effects on health and 
the environment. In the selection stage, we recommend 
that funding programmes should make collective deci-
sions that take environmental concerns into consider-
ation as well. In addition to planned research, also free-
ly selected research topics should deserve funding. State 
and private priorities should not interfere with the prin-
ciple of self-determination of research during selection 
and conduction of research and development activities.
For the benefit of society, we recommend investi-
gating the ecological and agronomic impact of the Swiss 
variety testing method more closely. As a preferred op-
tion, a comparative study should be conducted with se-
lected EU countries. Since the majority of farmers tend 
to follow informal cultivation recommendations, we fur-
ther suggest reconsidering the actual purposefulness of 
the mandatory catalogues of varieties. It might well be 
that their role as quality guarantors has been superseded 
by informal but more concrete cultivation recommenda-
tions. We suggest examining in greater detail whether 
the niche approval for native breeds is serving its pur-
pose or whether more approval opportunities should be 
provided for small-scale farming.
With a view to limiting health and environ-
mental hazards, we recommend extending the scope 
of the Genetic Engineering Act to specific highly inva-
sive breeding methods. Alternatively, regulations on 
environmental protection and variety approval should 
be amended to envisage also a risk assessment proce-
dure for these breeding methods. The risk assessment 
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procedures should be tailored to the specificities of se-
lective breeding methods. A more detailed study is re-
quired on the state, benefits and risks of the new breed-
ing methods that radically modify the genome.
We call for new studies on the lines of research 
in synthetic biology that are most likely to pose a serious 
threat to human beings or the environment, in order to 
have them included in the scope of the Genetic Engi-
neering Act. We also recommend developing new risk 
assessment methods that are specific to synthetic biolo-
gy. Such methods should identify appropriate tests to be 
conducted on the produced organisms.
The risk assessment of genetically modified or-
ganisms should be oriented towards “soft” genetic engi-
neering procedures. When the risk analysis comes to the 
conclusion that the marginal risk is uncertain, unlikely 
or negligible, we recommend that also the benefits pro-
vided by the organism should be described in detail and 
motivated.
We welcome the conclusion of voluntary agree-
ments for the coexistence of GMO and GMO-free farm-
ing through the creation of GMO-free areas. Addition-
ally, we recommend considering also ad-hoc spatial 
planning solutions. 
With respect to trade regulations, we suggest 
starting a political discussion and examining on the ba-
sis of surveys if specific production-related investment 
and import regulations should be introduced for biotech-
nical products. 
Since the modification of organisms evokes a po-
litically sensitive response in the community, we believe 
that the role of cultural typifications should be studied in 
greater detail in relation to the regulation of the biotech-
nical utilisation of genetic programmes in Switzerland 
and taken into account in the relevant regulatory frame-
works. We further propose that Switzerland should also 
enforce the labeling of foods obtained from animals fed 
with genetically modified feeds.
With reference to sharing the benefits deriving 
from the exploitation of genetic programmes located in 
Switzerland, we discourage the Federal Council from 
using its legislative powers to introduce provisions regu-
lating the access to genetic resources. Rather, we suggest 
examining more closely whether Switzerland as a User 
State is obliged and in the position to force its local data-
bases to ensure traceability of information to the State 
of origin and compliance with its conditions for access. 
We also recommend studying in greater detail how the 
entitlement to the sharing of benefits obtained from ge-
netic resources may get lost in the research and develop-
ment process.
In our view, it would be desirable to have a vari-
ety of multilateral arrangements for the sharing of bene-
fits obtained from the utilisation of genetic resources. 
They could be based on a number of instruments, rang-
ing from research cooperation to material and data pools 
through to financial funds. Switzerland could give its 
original contribution to the forthcoming international 
negotiations, thus taking its pioneering role in the de-
velopment of bilateral contractual solutions one step 
further.
In a nutshell, the authors make the following recommendations
• Targeted breeding, genetic engineering and synthet-
ic biology should not be seen in isolation but consid-
ered, examined and regulated as alternative types of 
biotechnical utilisation of genetic resources.
• In the regulation of property rights over genetic re-
sources, genetic information and genetically modified 
organisms, lawmakers should opt primarily for public 
rather than private ownership. 
• Funding for the biotechnical utilisation of genetic re-
sources should not be influenced by irrational fashion 
hypes that promote one or the other type of research. 
• The health and environmental hazards should be reg-
ulated so as to take into account the specific risks of the 
three mentioned biotechnologies. Furthermore, risk 
regulations should be more oriented towards a “soft 
biotechnology” and require that not only risk mini-
misation, but also the social benefits be demonstrated. 
• Cultural typifications of biotechnically modified or 
created organisms should be described more in detail 
and considered more thoughtfully in the regulatory 
framework. 
• Switzerland should also maintain freedom of access to 
its genetic resources and unvaried provisions on the 
sharing of the ensuing benefits.
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